GlassScriptPhysician profile
Justin Michael Croft
NPI 1770835522
$5,995.65
in general payments reported to CMS, 2019-2025
43 companies · $931 in 2025
The $931 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,469 · 2022: $1,136 · 2023: $1,336 · 2024: $1,125 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,391.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,007.99 | 2021-2025 | |
| Lilly USA, LLC | $735.99 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $609.51 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $586.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $441.83 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $276.70 | 2021-2025 | |
| Amarin Pharma, INC. | $222.72 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.90 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.09 | 2021-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $161.13 | 2021-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.02 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $87.15 | 2021 | |
| Antares Pharma, INC. | $81.55 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Novartis Pharmaceuticals Corporation | $79.14 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $74.01 | 2023-2024 | Quviviq |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $71.20 | 2021-2022 | |
| Amgen INC. | $66.75 | 2021-2024 | Repatha, Otezla |
| Neos Therapeutics, LP | $65.14 | 2021-2022 | |
| Corcept Therapeutics | $60.45 | 2025 | Korlym |
| Dexcom, INC. | $60.23 | 2022-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $59.10 | 2021-2023 | Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.33 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $54.45 | 2022 | |
| Azurity Pharmaceuticals, INC. | $54.12 | 2023 | Adthyza, Horizant |
| Boston Scientific Corporation | $50.41 | 2025 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $49.20 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $48.66 | 2023 | Rexulti |
| Electromed, INC. | $45.87 | 2025 | Smartvest |
| Lundbeck LLC | $45.56 | 2024 | Vyepti, Rexulti |
| Noven Therapeutics, LLC | $44.29 | 2024 | Xelstrym |
| Kowa Pharmaceuticals America, INC. | $41.00 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $39.57 | 2023-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $35.51 | 2023-2024 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $31.21 | 2021 | |
| Currax Pharmaceuticals LLC | $26.89 | 2021 | |
| Eisai INC. | $24.77 | 2021 | |
| Alfasigma USA, INC. | $24.01 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.20 | 2024 | Voquezna |
| Tris Pharma INC | $16.30 | 2024 | Dyanavel Xr |
| Shield Therapeutics INC | $13.70 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.06 | 2021 | |
| Vistapharm, INC. | $12.08 | 2021 | |
| Genentech USA, INC. | $10.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Croft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.